Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study.
- Published In:
- Acta pharmaceutica Sinica. B, 15(2), 707-721 (2025)
- Authors:
- Guo, Wei, Wen, Xuejun, Chen, Yuhang, Zhao, Tianzhi, Liu, Jia, Tao, Yucen, Fu, Hao, Wang, Hongjian, Xu, Weizhi, Pang, Yizhen, Zhao, Liang, Huang, Jingxiong, Xu, Pengfei, Guo, Zhide, Miao, Weibing, Zhang, Jingjing, Chen, Xiaoyuan, Chen, Haojun
- Database ID:
- RPEP-11222
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11222APA
Guo, Wei; Wen, Xuejun; Chen, Yuhang; Zhao, Tianzhi; Liu, Jia; Tao, Yucen; Fu, Hao; Wang, Hongjian; Xu, Weizhi; Pang, Yizhen; Zhao, Liang; Huang, Jingxiong; Xu, Pengfei; Guo, Zhide; Miao, Weibing; Zhang, Jingjing; Chen, Xiaoyuan; Chen, Haojun. (2025). Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study.. Acta pharmaceutica Sinica. B, 15(2), 707-721. https://doi.org/10.1016/j.apsb.2024.05.022
MLA
Guo, Wei, et al. "Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study.." Acta pharmaceutica Sinica. B, 2025. https://doi.org/10.1016/j.apsb.2024.05.022
RethinkPeptides
RethinkPeptides Research Database. "Safety, dosimetry, and efficacy of an optimized long-acting ..." RPEP-11222. Retrieved from https://rethinkpeptides.com/research/guo-2025-safety-dosimetry-and-efficacy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.